The company's average rating is Hold from 2 analysts.
We provide trade advice to complement the prevailing
expert consensus on Adamis Pharmaceuticl. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
The company has Profit Margin (PM) of
(298.84) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of
(225.25) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -2.25.
The successful prediction of Adamis Pharma
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Adamis Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Adamis Pharma based on Adamis Pharma hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Adamis Pharma's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Adamis Pharma's related companies.
Use Technical Analysis to project Adamis expected Price
Adamis Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, delisted stock market cycles, or different charting patterns.
A focus of Adamis Pharma technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Adamis Pharma trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Breaking it down
Adamis Pharmaceuticl reported the previous year's revenue of 16.53
M. Net Loss for the year was (49.39
M) with profit before overhead, payroll, taxes, and interest of 1.63
M.
Deferred Revenue Breakdown
Adamis Pharmaceuticl Deferred Revenue yearly trend continues to be very stable with very little volatility. Deferred Revenue is likely to drop to about 841.2
K. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Adamis Pharmaceuticl Deferred Revenue is very stable at the moment as compared to the past year. Adamis Pharmaceuticl reported last year Deferred Revenue of 950,070
| 2010 | 54,478 |
| 2017 | 14,758 |
| 2018 | 1.01 Million |
| 2019 | 915,671 |
| 2020 | 950,070 |
| 2021 | 841,179 |
Adamis Pharmaceuticl implied volatility may change after the decline
Recent value at risk is at -6.12. Adamis Pharmaceuticl is displaying above-average volatility over the selected time horizon. Investors should scrutinize Adamis Pharmaceuticl independently to ensure intended market timing strategies are aligned with expectations about Adamis Pharmaceuticl volatility. Adamis Pharmaceuticl is a potential penny stock. Although Adamis Pharmaceuticl may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Adamis Pharmaceuticl. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Adamis instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
The Current Takeaway on Adamis Pharmaceuticl Investment
Although other entities under the drug manufacturers—specialty & generic industry are still a bit expensive, Adamis Pharmaceuticl may offer a potential longer-term growth to insiders. With a less-than optimistic outlook for your 90 days horizon, it may be a good time to exit some or all of your Adamis Pharmaceuticl holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Adamis Pharmaceuticl.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Adamis Pharma. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
